<DOC>
	<DOCNO>NCT01275625</DOCNO>
	<brief_summary>One hundred subject Russia treat combination Combivir ( zidovudine lamivudine ) maraviroc first line HIV therapy . The aim ass efficacy safety combination Russian population patient .</brief_summary>
	<brief_title>Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia</brief_title>
	<detailed_description />
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Over 18 year age . R5 HIV infection screen tropism test . Viral load &gt; 1,000 copies/mL . Never previously treat antiHIV medicine . Previously treat antiHIV medicine . Hepatitis B coinfection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>maraviroc</keyword>
	<keyword>naive</keyword>
	<keyword>hiv</keyword>
	<keyword>zidovudine</keyword>
	<keyword>lamivudine</keyword>
	<keyword>combivir</keyword>
	<keyword>Clade A</keyword>
</DOC>